CompletedPhase 3NCT03281538
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cara Therapeutics, Inc.
- Principal Investigator
- Frederique MenzaghiCara Therapeutics
- Intervention
- CR845(drug)
- Enrollment
- 288 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (25)
- Cara Therapeutics Study Site, Chula Vista, California, United States
- Cara Therapeutics Study Site, El Centro, California, United States
- Cara Therapeutics Study Site, Long Beach, California, United States
- Cara Therapeutics Study Site, Northridge, California, United States
- Cara Therapeutics Study Site, Denver, Colorado, United States
- Cara Therapeutics Study Site, Hollywood, Florida, United States
- Cara Therapeutics Study Site, Tampa, Florida, United States
- Cara Therapeutics Study Site, Winter Park, Florida, United States
- Cara Therapeutics Study Site, Albany, Georgia, United States
- Cara Therapeutics Study Site, Augusta, Georgia, United States
- Cara Therapeutics Study Site, Meridian, Idaho, United States
- Cara Therapeutics Study Site, Springfield, Massachusetts, United States
- Cara Therapeutics Study Site, Roseville, Michigan, United States
- Cara Therapeutics Study Site, Kansas City, Missouri, United States
- Cara Therapeutics Study Site, Albuquerque, New Mexico, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03281538 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.